

April 30, 2014
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer

Notice Concerning Adjustment to Exercise Price of Stock Option

SymBio Pharmaceuticals Limited (“the Company”) announces that the exercise price of the Series 29 Stock Option of the Company will be adjusted due to the issuance of stock acquisition rights as stock options to the Company’s Directors and employees, which was resolved at the Board of Directors’ meeting on April 15, 2014.

1. Adjustment to Exercise Price

Description	Exercise Price after adjustment	Exercise Price before adjustment
SymBio Pharmaceuticals Limited Series 29 Stock Option	353.2 yen	354.4 yen

2. Effective Date

April 30, 2014 (Tuesday)

3. Reason for Adjustment

The issue price of the stock acquisition rights to the Company’s Directors and employees determined on April 30, 2014 is below the market price specified in the matters regarding adjustment of exercise prices of the guideline of the Series 29 Stock Option.

[Contact]

Investor Relations
Tel: +81(0)3 5472 1125